- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00403039
Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema
December 31, 2015 updated by: Vitreous -Retina- Macula Consultants of New York
Phase I Study of Intravitreally Administered Ranibizumab in 20 Subjects With Macular Edema Associated With CRVO.
The purpose of this study is to examine the effects of Lucentis for active Central Retinal Vein Occlusion with Macular Edema
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, Phase I study of intravitreally administered ranibizumab in 20 subjects with macular edema associated with CRVO.
Patients will be evaluated at baseline with ophthalmic examination, fluorescein angiography, optical coherence tomography, and color photography.
Subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered every 28 ± 2 days for a total of 3 injections.
Thereafter they are to be evaluated every month until month 12.
If the patients have signs of increased intraretinal hemorrhage or a persistence / increase in central macular edema as determined by optical coherence tomography when compared to their last visit, are eligible for re-injection at that monthly visit.
Study Type
Interventional
Enrollment (Actual)
41
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York City, New York, United States, 10022
- Vitreous Retina Macula Consultants of New York, P.C.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ability to provide written informed consent and comply with study assessments for the full duration of the study
- Age > 18 years
- Clinical evidence of perfused central retinal vein occlusion. A central retinal vein occlusion (CRVO) is defined as an eye that has retinal hemorrhages and a dilated retinal venous system in all 4 quadrants. Other evidence of a CRVO may include telangiectatic capillary bed and collateral vessels at the optic nerve head. .
- Central macular edema present on clinical examination and OCT testing with a central point thickness > 250 microns
- Visual acuity score greater than or equal to 34 letters (20/200) and less than or equal to 73 letters (20/40) by the ETDRS visual acuity protocol.
- Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography
Exclusion Criteria:
- Pregnancy (positive pregnancy test) or known to be pregnant, also premenopausal women not using adequate contraception.
- Participation in another simultaneous ocular investigation or trial
- Patient with uncontrolled hypertension
- Patient has a condition that, in the opinion of the investigator would preclude participation in the study (i.e. chronic alcoholism, drug abuse)
- Patient has significant diabetic retinopathy (greater than moderate NPDR) or macular edema associated with diabetic retinopathy
- Exam or OCT reveals evidence of vitreoretinal interface abnormality that may be contributing to the macular edema
- Eye that in the investigator has no chance of improvement in visual acuity following resolution of macular edema (i.e subretinal fibrosis or geographic atrophy)
- Any other additional ocular diseases which could irreversibly compromise the visual acuity of the study eye including amblyopia, anterior ischemic optic neuropathy (AION), age related macular degeneration (AMD), retinal detachment, severe cataracts, etc.
- Evidence of neovascularization of the iris or retina (presence of ischemic CRVO)
- History of Grid/Focal laser or Panretinal laser in the study eye
- History of vitreous surgery in the study eye
- History of use of intravitreal, peribulbar, or retrobulbar steroids within six months of the study.
- History of Cataract Surgery within 6 months of enrollment.
- History of YAG capsulotomy within 2 months of the surgery.
- Visual acuity <20/400 in the fellow eye
- Uncontrolled Glaucoma, pressure >30 despite treatment with glaucoma medications.
- Use of Bevacizumab in either eye within the past 30 days
- Use of Pegaptinib sodium in either eye within the past 6 weeks
- Use of Triamcinolone in either eye
- Have received any other systemic experimental drug within 12 weeks prior to enrollment.
- Unwilling or unable to follow or comply with all study related procedures.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Open-label ranibizumab
Subjects will receive open-label intravitreal injections of ranibizumab administered every 28 ± 7 days for a total of 3 injections.
Thereafter they are to be evaluated monthly for re-treatment until Month 48.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the safety and tolerability of 0.5 mg dose of Ranibizumab in the treatment of Macular Edema associated with CRVO
Time Frame: 72 months
|
72 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patients losing ≤ 15 letters as measured by ETDRS visual refraction at 4 meters compared to baseline at month 3, 6, 12, 24, 36, 48, 60 and 72
Time Frame: Months 3, 6, 12, 24, 36, 48, 60 and 72
|
Months 3, 6, 12, 24, 36, 48, 60 and 72
|
Proportion of patients gaining ≥ 15 letters as measured by ETDRS visual refraction at 4 meters compared to baseline at month 3, 6, 12, 24, 36, 48, 60 and 72.
Time Frame: Months 3, 6, 12, 24, 36, 48, 60 and 72
|
Months 3, 6, 12, 24, 36, 48, 60 and 72
|
Change in central retinal thickness as measured by OCT at months 3, 6, 9, 12, 24, 36, 48, 60 and 72 compared to baseline
Time Frame: Months 3, 6, 12, 24, 36, 48, 60 and 72
|
Months 3, 6, 12, 24, 36, 48, 60 and 72
|
Proportion of subjects losing ≥ 30 letters as measured by ETDRS visual refraction at month 6, 12, 24, 36, 48, 60 and 72
Time Frame: Months 6, 12, 24, 36, 48, 60 and 72
|
Months 6, 12, 24, 36, 48, 60 and 72
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Richard F. Spaide, M.D., Vitreous Retina Macula Consultants of New York, P.C.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2006
Primary Completion (Actual)
December 1, 2011
Study Completion (Actual)
December 1, 2011
Study Registration Dates
First Submitted
November 22, 2006
First Submitted That Met QC Criteria
November 22, 2006
First Posted (Estimate)
November 23, 2006
Study Record Updates
Last Update Posted (Estimate)
January 1, 2016
Last Update Submitted That Met QC Criteria
December 31, 2015
Last Verified
December 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Embolism and Thrombosis
- Venous Thrombosis
- Thrombosis
- Macular Degeneration
- Macular Edema
- Retinal Vein Occlusion
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Ranibizumab
Other Study ID Numbers
- FVF3851S
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinal Vein Occlusion
-
University of TorontoOntario Research FundUnknownCentral Retinal Vein Occlusion | Branch Retinal Vein Occlusion | Central Retinal Artery Occlusion | Branch Retinal Artery OcclusionCanada
-
University of TorontoPfizer; Unity Health Toronto; Canadian Heart Research Centre; Ontario Association... and other collaboratorsUnknownThrombosis | Central Retinal Vein Occlusion | Retinal Vein Occlusion | Branch Retinal Vein Occlusion | Retinal Vein ThrombosisCanada
-
Palo Alto Medical FoundationTerminatedCentral Retinal Vein Occlusion | Branch Retinal Vein OcclusionUnited States
-
Hanscom, Thomas, M.D.Genentech, Inc.CompletedCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionUnited States
-
Tokyo Medical UniversityUnknownCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionJapan
-
Justis EhlersRegeneron PharmaceuticalsCompletedCentral Retinal Vein Occlusion | Diabetic Macular Edema | Retinal Vein Occlusion | Branch Retinal Vein OcclusionUnited States
-
Hoffmann-La RocheChugai PharmaceuticalCompletedCentral Retinal Vein Occlusion | Macular Edema | Hemiretinal Vein OcclusionUnited States, Korea, Republic of, Brazil, Japan, United Kingdom, China, Argentina, Australia, France, Hungary, Italy, Poland, Spain, Singapore, Austria, Czechia, Germany, Hong Kong, Israel, Portugal, Russian Federation, Taiwan
-
Anders KvantaCompletedCentral Retinal Vein OcclusionSweden
-
He Eye HospitalUnknownCentral Retinal Vein OcclusionChina
-
He Eye HospitalUnknownBranch Retinal Vein OcclusionChina
Clinical Trials on Ranibizumab (Lucentis )
-
University of Illinois at ChicagoGenentech, Inc.WithdrawnGlaucoma | Neovascular Glaucoma | New Onset Glaucoma | New Onset Neovascular Glaucoma
-
Vista KlinikCompletedAge Related Macular Degeneration | Choroidal NeovascularizationSwitzerland
-
Retina Associates of Cleveland, IncGenentech, Inc.UnknownDepression | Central Retinal Vein Occlusion | Retinal Vein Occlusion | Venous Retinal Branch OcclusionUnited States
-
The National Retina InstituteGenentech, Inc.Completed
-
Southeast Clinical Research Associates, LLCGenentech, Inc.CompletedExudative Age Related Macular DegenerationUnited States
-
David M. Brown, M.D.Novartis PharmaceuticalsTerminatedAge-Related Macular DegenerationUnited States
-
Lawrence S. Morse, MDGenentech, Inc.CompletedAge Related Macular DegenerationUnited States
-
Johns Hopkins UniversityJuvenile Diabetes Research FoundationCompletedDiabetic Macular EdemaUnited States
-
Lahey ClinicWithdrawn
-
Mid-Atlantic Retina Consultations, Inc.CompletedMacular Degeneration | Choroidal Neovascularization